

February 14, 2024

The Honorable Brenda Landwehr, Chairperson  
House Committee on Health and Human Services  
300 SW 10th Avenue, Room 112-N  
Topeka, Kansas 66612

Dear Representative Landwehr:


**SUBJECT:** Fiscal Note for HB 2747 by House Committee on Health and Human Services

In accordance with KSA 75-3715a, the following fiscal note concerning HB 2747 is respectfully submitted to your committee.

HB 2747 would permit a pharmacist to screen and initiate prophylactic therapy for a patient for post-exposure to the human immunodeficiency virus within the statewide protocol adopted by the Collaborative Drug Therapy Management Committee. Currently, the committee is composed of three physicians appointed by the Board of Healing Arts and three pharmacists appointed by the Board of Pharmacy, plus a non-voting Chair from the Board of Pharmacy. This would be a change from current law which allows the Committee to adopt statewide protocols for a pharmacist to test the patient and, as appropriate, prescribe and dispense treatment for influenza, strep, and urinary tract infections. The Committee adopted statewide protocols for these conditions in 2023.

According to the Kansas Board of Pharmacy, enactment of HB 2747 would increase costs to the Board in the form of staff time and resources necessary to carry out such duties. The Board estimates that it would possibly increase costs for temporary staff and meetings by \$4,320 from the Board of Pharmacy Fee Fund for FY 2025. Any fiscal effect associated with HB 2747 is not reflected in *The FY 2025 Governor's Budget Report*.

Sincerely,



Adam C. Proffitt  
Director of the Budget

cc: Alexandra Blasi, Board of Pharmacy